Loading
A phase 1/2 trial of U32 CAR-T in acute myeloid leukaemia, run by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, now recruiting.
Clinical Study of U32 in Patients With Acute Myeloid Leukemia is a phase 1/2 interventional study registered as NCT07036250 by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, with 20 participants planned, started 2025-07-03 and due to reach its primary completion in 2027-12-31. Interventions recorded: U32 CAR-T.
Shares Unicar-Therapy and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares CAR-T cell therapy and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.